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INTRODUCTION:  Non-urothelial  tumours  are  rare  and  account  for less  than  5%  of  all  bladder  tumours.
Bladder  paragangliomas  also  known  as  extra-adrenal  pheochromocytomas  are  of  the  non-urothelial
subgroup.  We present  an  unusual  case  of asymptomatic  bladder  paraganglioma.
CASE  REPORT:  A  77 year  old  lady  presented  with  acute  abdominal  pain  was  found  to  have  an  incidental
enhancing  nodule  in  the bladder.  During  cystoscopy  and  transurethral  resection  the patient  experienced
signiﬁcant  ﬂuctuations  in  blood  pressure  that  required  anaesthetic  adjustments.  Review  of  histology
conﬁrmed  a diagnosis  of  bladder  paraganglioma.
DISCUSSION:  Most  bladder  paraganglioma  cases  present  with  sympathomimetic  related  symptoms  and
microscopic  haematuria  but our  patient  was  asymptomatic  which  resulted  in  inadequate  pre-operative
optimisation  and high  anaesthetic  risk.  Majority  of paragangliomas  are  benign  but there  is  a  20-40%
chance  of  malignancy.  The  management  options  will  predominantly  depend  on  whether  disease  isase report localised,  regional,  metastatic  or recurrent  in nature.
CONCLUSION:  Due  to  the  non-speciﬁc  nature  of  disease,  variability  of presentations  and  rare  incidence,
bladder  paragangliomas  are  often  not  part  of the  urologists’  differential  diagnoses.  In our  opinion,  estab-
lishing  guidelines  should  assist  to  achieve  a balance  between  anaesthetic  risks,  cystoscopy  and  follow
up.
© 2016  Published  by Elsevier  Ltd on  behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open  access  article
he CCunder  t
. Introduction
Bladder tumours can be subdivided into urothelial and non-
rothelial tumours. They usually present as urothelial tumours,
ith non-urothelial tumours accounting for less than 5% of all blad-
er tumours. Bladder paragangliomas (also known as extra-adrenal
heochromocytomas) are of the non-urothelial subgroup [1]. We
resent an unusual case of asymptomatic bladder paraganglioma.
. Case report
A 77 year old lady presented to the emergency department with
cute abdominal pain. A Computed Tomography (CT) abdomen
nd pelvis with contrast performed demonstrated an inciden-
al enhancing nodule anteriorly in the bladder measuring 2.2 cm
Figs. 1 and 2). The patient was referred to the urology multi-
isciplinary team (MDT) which decided further investigation was
arranted with cystoscopy and a transurethral resection.
During the resection under general anaesthesia, the patient
xperienced signiﬁcant ﬂuctuations in blood pressure (BP) that
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required intermittent breaks and pharmacological adjustment.
Macroscopically the tumour was  a tan brown lesion with normal
smooth bladder mucosa.
Review of histology conﬁrmed a diagnosis of a bladder paragan-
glioma (Figs. 3, 4 and 5). CD56 and chromogranin immunostains
are commonly used neuroendocrine markers. The brown staining
on both immunostains shows evidence for neuroendocrine cells. As
the patient had multiple intra-abdominal surgeries and there was
no evidence of metastatic spread on the CT scan, the MDT’s decision
was for 3 monthly follow-up with surveillance cystoscopies post-
resection and depending on clinical features for further biochemical
and radiological investigations as needed.
3. Discussion
The incidence of bladder paragangliomas is less than 0.05% of all
bladder tumours [2] and less than 1% of all paragangliomas [3]. The
mean patient age was 43.3 years (range 11-84) and has an almost
equal male to female ratio of 1.07:1 [4].
A systemic review found 106 patients and demonstrated that
majority of cases presented with catecholamine secretion lead-
ing to sympathomimetic related symptoms. The most common
symptoms at presentation in decreasing order are hypertension,
headaches, haematuria and syncope/palpitations [3]. They are often
triggered during micturition hence termed ‘micturition attacks’ and
s an open access article under the CC BY-NC-ND license (http://creativecommons.
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Fig. 1. Coronal view showing bladder enhancing nodule.
Fig. 2. Axial section demonstrating bladder enhancing nodule.
Fig. 3. Low power view with Hematoxylin & Eosin stain demonstrating the solid
tumour compressing muscle.
Fig. 4. CD56 stain with brown colour highlighting positive paraganglioma tumour
cells. No necrotic areas or mitoses were seen. Antigen Ki-67 is less than 5%.Fig. 5. Chromogranin immunostain with brown colour demonstrating positive neu-
roendocrine cells.
are reported in 52.8% of patients [3]. Patients were reported to
have haematuria in 47-60% of cases and most were of microscopic
nature [3,5]. The literature dictates that only 27% of patients had no
indication of hormonal activity [6], and 3% of cases were inciden-
tal ﬁndings [3]. Our patient had moderate hypertension controlled
with one anti-hypertensive, did not experience any other symp-
toms and had a negative urine specimen.
In an asymptomatic incidental bladder lesion it is almost
impossible to diagnose bladder paraganglioma without histological
diagnosis. Suspicious cases are usually investigated by measur-
ing the level of catecholamine and its metabolites (metanephrine
and vanillylmandelic acid secretion) in blood and urine [7,8]. A
ﬂexible cystoscopy may  be warranted as a form of preliminary
investigation especially in symptomatic patients. CT or Magnetic
Resonance Imaging can identify the location and extent of the inva-
sion. Advanced methods with the use of nuclear medicine scanning
using radioisotope 123- or 131-iodine-metaiodinebenzylguinidine
and Positron Emission Tomography should be considered, and is
the imaging modality of choice for localizing small tumours [9–11].
Prior to any surgical intervention, careful pre-operative man-
agement is required. A pre-operative treatment period of 1-3
weeks with alpha-adrenergic blockade is recommended to avoid
intra/post-operative complications such as hypertensive crisis,
arrhythmias, myocardial infarction and pulmonary oedema. Beta-
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drenergic blockade can be considered pre-operatively, especially
n patients with persistent arrhythmias or tachycardia, but must
ever be initiated before alpha-adrenergic blockade because doing
o leads to unopposed alpha-adrenergic vasoconstriction which
an lead to a life-threatening crisis [12]. Good symptomatic con-
rol and a target low BP for age are features of adequate medical
ptimisation.
The macroscopic appearance of tan brown lesion seen on cys-
oscopy is not pathognomic for any form of bladder tumour.
ccording to literature, majority of paragangliomas are benign with
 20-40% of chance of malignancy [13]. There is no single parame-
er that can predict the malignant potential of paragangliomas. In
ractice, the only reliable criterion for malignancy is the presence of
istant metastases [12]. At present, novel molecular biomarkers are
eing investigated for their utility in deﬁning malignant tumours.
The management options will predominantly depend on
hether disease is localised, regional, metastatic or recurrent in
ature. Patients with disease dissemination will require man-
gement with a combination of surgery, chemotherapy and/or
adiotherapy [14,15]. There is currently no consensus on the
anagement of localised/regional cases. Some studies advocate a
artial or complete cystectomy as there is a chance of recurrence
rom chromafﬁn cells in the sympathetic plexus of detrusor muscle,
nd a transurethral resection approach does not adequately excise
he lesion. Most however agree that regular follow-up is necessary
13]. Prognostic factors that can be used as a guide include large
ize (>5 cm diameter), local tumour extension, and the presence of
ecrotic areas [12,13].
. Conclusion
Due to the non-speciﬁc nature of disease, variability of presenta-
ions and rare incidence, bladder paragangliomas are often not part
f the urologist’s differential diagnoses. This article hopes to add
o the limited cases of asymptomatic incidental bladder paragan-
liomas in the literature and illustrate the importance of suspecting
ts possibility to reduce operative risk. The involvement of the MDT
s essential to ensure patient safety. We  support the notion that all
ases necessitate long-term follow up which will be dictated by the
xtent of disease involvement. In our opinion, establishing guide-
ines should assist to achieve a balance between anaesthetic risks,
ystoscopy and follow up. Further research is required to establish
est practice in localised bladder paraganglioma management.
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